PROSPECT IIA large multi-center prospective study was designed to assess the ability of intravascular imaging to identify non-obstructive coronary plaque that may cause future adverse events. After successfully treating all flow-limiting lesions in patients with recent myocardial infarction, investigators performed NIRS+IVUS intravascular imaging of all three coronary arteries. Patients were then followed for any adverse events that may have been caused by previously identified untreated non-culprit lesions.
PROSPECT ABSORBA sub-study embedded in the present study. Patients with angiographically, non-obstructive lesions with site-determined IVUS plaque burden were randomized to treatment with a bioresorbable scaffold versus medical therapy alone. These patients underwent repeat angiography and intravascular imaging at 25 months.
The Makoto™ Intravascular Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, is the only FDA-cleared imaging system indicated for the detection of plaque and patients at higher risk of MACE.
To request more information on how to obtain the Makoto™ system, or to see a demo, CLICK HERE
© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative